India's Amaravati to Deploy an IBM Quantum Computer in September

en.Wedoany.com Reported - IBM Chairman and CEO Arvind Krishna confirmed that India's emerging city of Amaravati will host one of the country's first two physical IBM quantum computers, with the hardware slated to be fully operational by September 2026. This deployment is a key component of the Andhra Pradesh Quantum Valley initiative, aiming to transform the regional capital into a major deep-tech innovation hub in India and shift the nation's role from remotely consuming cloud computing modules to independently developing localized physical quantum hardware.

The upcoming hardware is being advanced under a tripartite memorandum of understanding signed by the Andhra Pradesh government, IBM, and Tata Consultancy Services (TCS). Subject to standard international export licensing frameworks and final technical agreements, the site is planned to be equipped with an IBM Quantum System Two featuring a 156-qubit Heron quantum processor. Krishna noted that the commercialization of quantum computing in areas such as pharmaceuticals, advanced artificial intelligence, financial fraud analysis, and materials science will take another two to three years to deliver market advantages, making early infrastructure ownership crucial for developing localized intellectual property.

The construction of the Quantum Valley tech park in Uddandarayunipalem complements the recently launched Amaravati Quantum Reference Facility (AQRF) in the state. Supported by India's 600 billion rupee National Quantum Mission, this ecosystem has already brought together over 50 foundational partners, including Larsen & Toubro (L&T), C-DAC, C-DOT, and top academic institutions, aiming to build an end-to-end local supply chain. By embedding the physical 156-qubit processor into local infrastructure, the project plans to cultivate regional talent in quantum mathematics and physics, creating a highly skilled workforce capable of designing unbreakable national security communication networks and running complex molecular drug discovery simulations locally.